NICE wobbles

Journal of the Royal Society of Medicine

Volumn 102, Issue 6, 2009, Pages 212-213

  Maynard, Alan ^a   Bloor, Karen ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; TRASTUZUMAB;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MARKETING; EDITORIAL; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE ACCESS; NATIONAL HEALTH ORGANIZATION; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RESOURCE ALLOCATION; TERMINAL CARE;

EID: 67649277640     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.2009.09k031     Document Type: Editorial

References (13)

1. Jay A, ed. The Oxford dictionary of political quotations. Oxford: Oxford University Press; 1996
2. House of Commons Health Committee; National Institute for Health and Clinical Excellence. First Report of Session 2007-2008. HC 27-31 London: The Stationery Office; 2008
3. Richards M. Improving access to medicines for NHS patients: A report for the Secretary of State for Health. London: Department of Health; 2008
4. Department of Health. Guidance on NHS patients who wish to pay for additional private care. London: Department of Health; 2009
5. Nikolentzos A, Nolte E, Mays N. Paying for (expensive) drugs in the statutory system: an overview of experiences in 13 countries. London: Department of Health; 2008
6. Office of Fair Trading. The Pharmaceutical Price Regulation Scheme - An OFT market study. London: Office of Fair Trading; 2007
7. Claxton K, Briggs A, Buxton M, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008;336:251-254
8. Department of Health and Association of the British Pharmaceutical Industry. The Pharmaceutical Price Regulation Scheme. London: Department of Health; 2008
9. Pickin M, Cooper CL, Chater T, et al. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study - early results and lessons for the future. BioMedCentral Neurology 2009;9:1-8
10. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgements. BMJ 2004;329:224-227
11. Towse A. Should NICE's threshold range for cost per QALY be raised? Yes. BMJ 2009;338:b181
12. Raftery J. Should NICE's threshold range for cost per QALY be raised? No. BMJ 2009;338:b185
13. Martin S, Rice N, Smith PC. Further evidence on the link between health care spending and health outcomes. CHE Research Paper 32. York: Centre for Health Economics, University of York; 2007